Chahra Louafi - DBV Technologies Director
| DBV Stock | EUR 1.17 0.03 2.63% |
Director
Ms. Chahra Louafi was Director Representative of CDC Entreprises at DBV Technologies SA since December 16, 2010. She is the Investment Director for CDC Entreprises, Fund Management for InnoBio. Before joining CDC Entreprises in 2001, Ms. Louafi was in charge of initiating and implementing projects, as well as creating in a private business incubator specialized in biotechnology, Mendel Partner. Within CDC Entreprises, she was in charge, inter alia, of funds of funds investments focused on seed funds and biotech funds, and tech transfer transactions. In October 2009, she joined the management team of InnoBio fund, a fund dedicated to biotech companies, managed by CDC Entreprises and invested by the pharmaceutical industry since 2010.
| Tenure | 14 years |
| Phone | 33 1 55 42 78 78 |
| Web | https://www.dbv-technologies.com |
DBV Technologies Management Efficiency
The company has return on total asset (ROA) of (0.2178) % which means that it has lost $0.2178 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4299) %, meaning that it generated substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Peter Murphy | NorAm Drilling AS | 55 | |
| Douglas Harrison | Superior Plus Corp | 58 | |
| Mary Jordan | Superior Plus Corp | 58 | |
| Craig Jacobson | NorAm Drilling AS | 65 | |
| Walentin Mirosh | Superior Plus Corp | 71 | |
| David Smith | Superior Plus Corp | 59 | |
| Michael Kreger | NorAm Drilling AS | 33 | |
| Peter Kern | NorAm Drilling AS | 50 | |
| Patrick Gottschalk | Superior Plus Corp | 54 | |
| Ross Levinsohn | NorAm Drilling AS | 54 | |
| Laura Walker | NorAm Drilling AS | 60 | |
| Richard Bradeen | Superior Plus Corp | 61 | |
| Eugene Bissell | Superior Plus Corp | 64 | |
| Robert Engbloom | Superior Plus Corp | 64 | |
| Catherine Best | Superior Plus Corp | 64 | |
| James Arestia | NorAm Drilling AS | N/A | |
| Randall Findlay | Superior Plus Corp | 67 | |
Management Performance
| Return On Equity | -0.43 | |||
| Return On Asset | -0.22 |
DBV Technologies Leadership Team
Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pascale Ehouarn, Industrial Development and Production Director | ||
| Claude Thebault, Medical Director | ||
| Wence Agbotounou, Chief Clinical Trial Officer | ||
| Laurent Martin, Director of Regulatory Affairs | ||
| Viviane Monges, Director | ||
| Caroline Daniere, Chief Staff | ||
| Didier Hoch, Director | ||
| Daniel Tass, CEO Director | ||
| Hugh Sampson, Chief Scientific Officer | ||
| Pascal Wotling, Chief Officer | ||
| Charles Ruban, Chief Development Officer | ||
| Nathalie Donne, Director of Corporate Communication & Business Development | ||
| Lucie Mondoulet, Director of Research | ||
| Anne Pollak, Head Relations | ||
| Chahra Louafi, Director - Representative of CDC Entreprises (Innobio) | ||
| Peter Hutt, Independent Director | ||
| Michele Robertson, Chief Officer | ||
| Rafaele Tordjman, Director - Representative of Sofinnova Partners | ||
| Bertrand Dupont, Chief Technical Officer | ||
| Joseph Becker, VP Communications | ||
| Sbastien Robitaille, Chief Officer | ||
| Veronique Foutel, Chief Strategic Marketing Officer | ||
| Daniel Tasse, CEO | ||
| Rafale Tordjman, Director - Representative of Sofinnova Partners | ||
| Joan Schmidt, Executive Vice President General Counsel | ||
| George Horner, Director | ||
| Torbjorn Bjerke, Independent Director | ||
| Pharis Mohideen, Chief Medical Officer | ||
| PierreHenri Benhamou, Chairman of the Board, CEO | ||
| Torbjrn Bjerke, Independent Director | ||
| Mailys Ferrere, Director | ||
| Michel Rosen, Director | ||
| David Schilansky, CFO |
DBV Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (8.04) % | |||
| Current Valuation | 51.36 M | |||
| Shares Outstanding | 93.97 M | |||
| Shares Owned By Insiders | 6.50 % | |||
| Shares Owned By Institutions | 33.06 % | |||
| Price To Earning | (14.30) X | |||
| Price To Book | 1.18 X | |||
| Price To Sales | 28.05 X |
Pair Trading with DBV Technologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DBV Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DBV Technologies will appreciate offsetting losses from the drop in the long position's value.Moving together with DBV Stock
| 0.76 | CSJA | CSL LTD SPONADR | PairCorr |
| 0.72 | CSJ | CSL Limited | PairCorr |
| 0.72 | VX1 | Vertex Pharmaceuticals | PairCorr |
Moving against DBV Stock
| 0.92 | MBG | Mercedes Benz Group Earnings Call This Week | PairCorr |
| 0.81 | DBPE | Xtrackers LevDAX | PairCorr |
| 0.76 | KB9 | KBC Ancora SCA | PairCorr |
| 0.74 | NOVA | Novo Nordisk AS | PairCorr |
| 0.71 | GOC | Star Diamond | PairCorr |
The ability to find closely correlated positions to DBV Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DBV Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DBV Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DBV Technologies SA to buy it.
The correlation of DBV Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DBV Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DBV Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DBV Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DBV Technologies SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in DBV Stock please use our How to Invest in DBV Technologies guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for DBV Stock analysis
When running DBV Technologies' price analysis, check to measure DBV Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBV Technologies is operating at the current time. Most of DBV Technologies' value examination focuses on studying past and present price action to predict the probability of DBV Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBV Technologies' price. Additionally, you may evaluate how the addition of DBV Technologies to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |